Details of the Drug

General Information of Drug (ID: DMFJH5Q)

Drug Name
Mephentermine
Synonyms
Mefenterdrin; Mefentermin; Mefentermina; Mephenterdrine; Mephenterdrinum; Mephenterminum; Mephetedrine; Mephine; Vialin; Wyamine; Wyfentermina; Mefentermina [INN-Spanish]; Mephentermine (INN); Mephentermine [INN:BAN]; Mephenterminum [INN-Latin]; N-Methylphentermine; WY-585; Mephentermine Sulfate (2:1); N,alpha,alpha-Trimethylbenzeneethanamine; N,alpha,alpha-Trimethylphenethylamine; Omega-Phenyl-tert-butyl-methylamine; N-Methyl-omega-phenyl-t-butylamine; N-Methyl-omega-phenyl-tert-butylamine; N,2-dimethyl-1-phenylpropan-2-amine; 2-Methyl-2-methylamino-1-phenylpropane; 2-Methylamino-2-methyl-1-phenylpropane
Indication
Disease Entry ICD 11 Status REF
High blood pressure BA00 Approved [1]
Therapeutic Class
Vasoconstrictor Agents
Affected Organisms
Humans and other mammals
ATC Code
C01CA11: Mephentermine
C01CA: Adrenergic and dopaminergic agents
C01C: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01: CARDIAC THERAPY
C: CARDIOVASCULAR SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 163.26
Logarithm of the Partition Coefficient (xlogp) 2.4
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 17 - 18 hours [2]
Metabolism
The drug is metabolized via the hepatic []
Chemical Identifiers
Formula
C11H17N
IUPAC Name
N,2-dimethyl-1-phenylpropan-2-amine
Canonical SMILES
CC(C)(CC1=CC=CC=C1)NC
InChI
InChI=1S/C11H17N/c1-11(2,12-3)9-10-7-5-4-6-8-10/h4-8,12H,9H2,1-3H3
InChIKey
RXQCGGRTAILOIN-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3677
ChEBI ID
CHEMBL6755
CAS Number
100-92-5
UNII
TEZ91L71V4
DrugBank ID
DB01365
TTD ID
D0G1OZ
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Agonist [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease High blood pressure
ICD Disease Classification BA00
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mephentermine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Increased risk of hyperpyrexia by the combination of Mephentermine and Methylene blue. Acquired methaemoglobinaemia [3A93] [4]
Droxidopa DM5YF4M Moderate Additive hypertensive effects by the combination of Mephentermine and Droxidopa. Autonomic nervous system disorder [8D87] [5]
Levomilnacipran DMV26S8 Moderate Increased risk of rapid heart rate by the combination of Mephentermine and Levomilnacipran. Chronic pain [MG30] [6]
Milnacipran DMBFE74 Moderate Additive hypertensive effects by the combination of Mephentermine and Milnacipran. Depression [6A70-6A7Z] [6]
Desvenlafaxine DMHD4PE Moderate Increased risk of rapid heart rate by the combination of Mephentermine and Desvenlafaxine. Depression [6A70-6A7Z] [6]
Ozanimod DMT6AM2 Moderate Increased risk of hyperpyrexia by the combination of Mephentermine and Ozanimod. Multiple sclerosis [8A40] [4]
Safinamide DM0YWJC Moderate Decreased metabolism of Mephentermine caused by Safinamide mediated inhibition of non-CYP450 enzyme. Parkinsonism [8A00] [7]
Rasagiline DM3WKQ4 Moderate Additive hypertensive effects by the combination of Mephentermine and Rasagiline. Parkinsonism [8A00] [4]
⏷ Show the Full List of 8 DDI Information of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J. 1976 Nov;92(5):661-4.
4 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
5 Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
6 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
7 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".